Table 1 Baseline clinical features of the total iNPH sample
Total iNPH samples | Bologna cohort | Kuopio cohort | p-value | |
|---|---|---|---|---|
293 | 127 | 166 | ||
Males, n (%) | 171 (58.4) | 83 (65.4) | 88 (53.0) | 0.034 |
Age at evaluation, years | 75.4 ± 5.7 | 75.7 ± 5.1 | 75.1 ± 6.5 | 0.53 |
BMI, (kg/m2) | 27.0 (24.5–29.3) | 26.8 (24.2–29.6) | 27.0 (24.7–29.1) | 0.86 |
Age at disease onset, years | 73.0 (69.0–77.0) | 73.0 (69.0–76.0) | 72.9 (68.7–78.3) | 0.5 |
Disease duration < 12 months, n (%) | 53 (18.5) | 21 (16.5) | 32 (19.3) | 0.68 |
Symptoms at first evaluation | ||||
Gait disorders, n (%) | 285 (97.3) | 119 (98.4) | 166 (100) | 0.18 |
Urinary dysfunctions, n (%) | 243 (82.9) | 100 (78.7) | 143 (86.1) | 0.42 |
Cognitive impairment, n (%) | 220 (75.1) | 83 (65.4) | 137 (82.5) | 0.004 |
Urinary dysfunctions | ||||
Urinary incontinence, n (%) | 159 (54.3) | 74 (58.3) | 85 (51.2) | 0.037 |
Urinary urgency, n (%) | 241 (82.3) | 98 (77.2) | 143 (86.1) | 0.05 |
Gait Speed (m/s) | 0.69 ± 0.31 | 0.70 ± 0.27 | 0.67 ± 0.34 | 0.25 |
Scores | ||||
iNPH grading scale (max 12) | 6 (4–8) | 6 (4–7) | 7 (4–9) | 0.01 |
mRankin Scale (max 6) | 2 (2–3) | 2 (1–3) | 3 (2–3) | 0.001 |
MMSEc (max 30) | 25 (21–27) | 26 (24–28) | 23 (20–26) | 0.001 |
Dopaminergic treatment | ||||
Levodopa treatment, n (%) | 40 (13.7) | 36 (28.4) | 4 (2.4) | < 0.001 |
Levodopa max daily posology (mg) | 300 (300–450) | 300 (300–450) | 450 (200–800) | 0.64 |
Other antiparkinsonian drugs, n (%) | 10 (3.4) | 6 (4.7) | 4 (2.4) | 0.28 |
Shunt Surgery, n (%) | 255 (87.0) | 89 (70.1) | 166 (100) | < 0.001 |
Biomarkers | ||||
α-syn RT-QuIC + , n (%) | 60 (20.5) | 28 (22.1) | 32 (19.1) | 0.56 |
t-tau (pg/ml) | 184 (137–252) | 189 (142–256) | 182 (129–240) | 0.13 |
p-tau (pg/ml) | 28 (20–40) | 26 (21–35) | 30 (17–43) | 0.82 |
NfL (pg/ml) | – | 1018 (755–1483) | – | – |
Aβ42 (pg/ml) | 573 (424–777) | 495 (365–714) | 662 (513–856) | < 0.001 |
Aβ42/40 ratio | – | 0.84 ± 0.21 | – | – |
Aß + §, n (%) | 60 (24.0) | 32 (25.2) | 28 (22.4) | 0.58 |